Vanda’s phase III trial for social anxiety drug fails
Vanda Pharmaceuticals (VNDA) reported that its phase III trial for VQW-765, a drug for social anxiety, failed to meet primary and secondary endpoints. The study showed no significant difference in distress levels between the drug and placebo. The company has paused the program pending further analysis. The drug was safe and well-tolerated, according to the company.
How this was made
The 30-second read
Why it matters
The failure erases near‑term revenue expectations from the program and may affect the company's cash runway and valuation.
Market read
The announcement contributed to a broader tech market decline as investors priced in heightened risk for biotech trial outcomes.
What to watch
Potential for a future NDA filing if additional data supports efficacy; partnership with Novartis could mitigate downside.
Background
Vanda Pharmaceuticals disclosed its Phase III results for VQW-765, a nicotinic receptor partial agonist licensed from Novartis, targeting social anxiety disorder.
Ticker impact
Phase III trial of VQW-765 for social anxiety failed to meet primary and key secondary endpoints, announced today.
likely pressure as the market prices in the failed trial data
First disclosure of a pivotal Phase III failure for a listed biotech; investors typically react sharply to such news.
Market effects
May dampen sentiment for anxiety‑disorder therapeutics and broader biotech trial pipelines.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond biotech sector.
Counterpoint
If the company can pivot the asset to a different indication, the drop may be overstated.
Key entities
- companyVanda Pharmaceuticals Inc.
US‑listed biotech developing VQW-765 for social anxiety.
- companyNovartis
Original licensor of the VQW-765 molecule.
